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Pregnancy has been linked to various microangiopathies, including primary
atypical haemolytic uraemic syndrome (aHUS). Complement dysregulation,
often linked to rare variants in complement genes, is key for primary aHUS
to manifest and may play a role in pregnancy complications of the mother
and fetus. The burden of such complications is unknown, making coun-
selling of women with primary aHUS and asymptomatic relatives difficult.
We analyzed the maternal and fetal outcomes of 39 pregnancies from 17
women with primary aHUS and two asymptomatic relatives. Seven out of
39 pregnancies were complicated by pregnancy-associated aHUS. Five out
of 32 pregnancies not linked to pregnancy-associated aHUS were compli-
cated by pre-eclampsia or HELLP. Rare genetic variants were identified in
10 women (asymptomatic relatives, n = 2) who had a total of 14 pregnan-
cies, including 10 uncomplicated pregnancies. Thirty-five out of 39 preg-
nancies resulted in live birth. Eight out of 19 women had progressed to
end-stage kidney disease, with an incidence of 295 (95% confidence inter-
val, 137–561) per 100 person-years after the first pregnancy. Thus, we
emphasized the frequency of successful pregnancies in women with primary
aHUS and asymptomatic relatives. Pregnancies should be monitored clo-
sely. Rare genetic variants cannot predict the risk of a given pregnancy.
Keywords: primary atypical haemolytic uraemic syndrome, thrombotic
microangiopathy, pregnancy, complement, genetics.
Healthy pregnancy has been linked to significant haemody-
namic and immunologic shifts for maternal adaptation, pla-
centation and fetal tolerance. Defects in these processes can
lead to a spectrum of microangiopathies, having great impact
on maternal and fetal morbidity and mortality. Microangio-
pathic disorders of pregnancy range from pre-eclampsia to
HELLP (i.e. haemolysis, elevated liver enzymes, low platelets)
and, although rare, the syndromes of thrombotic microan-
giopathy (TMA), including thrombotic thrombocytopenic
purpura and primary atypical haemolytic uremic syndrome
(aHUS). Most of these microangiopathies occur late in preg-
nancy, suggesting a common denominator. In the last
decade, complement has been linked to the mechanism of
primary aHUS, either related to pregnancy1 or not,2,3 and, to
a lesser extent, pre-eclampsia4 and HELLP.5,6
The complement cascade is part of innate immunity and
an effector system involved in host homeostasis and the
defence against pathogens, which can be activated via the
classic, lectin and alternative pathway (AP).7 The latter is a
continuously active surveillance system operating in the cir-
culation and on cell surfaces. Host cells, including those from
the placenta, are protected from the harmful effects of com-
plement by regulatory proteins. Of note, tight complement
regulation at the feto–maternal surface is crucial for
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pregnancy to succeed.8 Rare variants in genes encoding pro-
teins that either regulate or activate complement and/or
autoantibodies that affect AP regulation can cause comple-
ment dysregulation and are prevalent in primary aHUS.2,3
These abnormalities per se are not sufficient for TMA to
occur. Pregnancy, however, may precipitate the onset or sub-
sequent relapses of life-threatening episodes of primary
aHUS.9 Furthermore, the incidence of pre-eclampsia and
HELLP may be higher in pregnant women with primary
aHUS.9
The risk for complications in pregnant women prone for
complement dysregulation, that is, patients with primary
aHUS and asymptomatic relatives carrying rare variants in
complement genes, is therefore considered high. In clinical
practice, however, it is difficult to counsel such women as
robust clinical data are lacking.10 Moreover, the impact of
pregnancies on fetuses and the role of prophylactic measures
remain to be established.11 The current study focussed on
maternal and fetal outcomes of 39 pregnancies in a well-de-
fined cohort of women with primary aHUS and asymp-




Female patients with TMA and at least one reported preg-
nancy were recruited from the Limburg Renal Registry,
Maastricht, The Netherlands,12 and the Cliniques universi-
taires Saint-Luc, Brussels, Belgium. TMA was defined as typi-
cal morphologic features of TMA on kidney biopsy or
microangiopathic haemolytic anaemia (haematocrit <30%,
haemoglobin <10 g/l, lactate dehydrogenase >500 U/l and
schistocytes on peripheral blood smear), platelets <150 G/l
and acute kidney injury in patients with no pathologic proof
of TMA. Patients with primary aHUS, defined as TMA, enzy-
matic activity of ADAMTS13 (i.e. von Willebrand factor pro-
tease) of at least 10%, and proven complement defects as
detailed below,13 were included. Patients with the onset of
TMA during pregnancy or within the first 12 weeks postpar-
tum were classified as pregnancy-associated aHUS (P-
aHUS).9 Also, asymptomatic female relatives carrying rare
variants in complement genes were included; relatives from
patients with primary aHUS, either related to pregnancy or
not, were screened at the discretion of the physician. Disease
definitions for pre-eclampsia,14 HELLP,15 and chronic kidney
disease (CKD)16 were based on standard international crite-
ria. End-stage kidney disease (ESKD) was defined as the need
for renal replacement therapy. Normal birth weight was
defined as a birth weight between the 10th and 90th per-
centiles corrected for gender and gestational age; small for
gestational age was defined as a birth weight <10th percentile
corrected for gender and gestational age.17
The clinical data were obtained from the Limburg Renal
Registry and/or the patients’ medical records. The study was
approved by the appropriate ethics committees and is in
accordance with the Declaration of Helsinki.
Complement analysis
DNA was tested for rare variants, that is, variants with a
minor allele frequency <1%, and single nucleotide polymor-
phisms in coding regions of CFH, CFI, CD46, CFB, C3,
CFHR1-5, THBD and DGKE using sequencing.18 Rare vari-
ants were classified according to international standards.19
Pathogenic variants were defined as those with functional
studies supporting a defect in complement regulation,
including null variants in genes linked to complement regu-
lation and variants that cluster in patients with primary
aHUS as demonstrated by Osborne et al.20 Likely pathogenic
variants were defined as those with functional studies sup-
porting a defect in complement regulation that were located
in a mutational hotspot and critical functional domain. The
CFH-CFHR1-5 genomic region was analyzed for rearrange-
ments by multiplex ligation probe amplification.21 Factor H
autoantibodies were assessed by enzyme-linked immunosor-
bent assay in selected cases.22
Patients with no variants identified were screened for
unrestrained ex vivo C5b9 formation on microvascular
endothelial cells of dermal origin (HMEC-1; ATCC, Manas-
sas, VA, USA) as described.23,24 Briefly, HMEC-1 were used
when >80% confluent, incubated with serum diluted in test
medium for 3 h at 37°C, fixed in 3% formaldehyde and
blocked with 2% bovine serum albumin for 1 h. Rabbit anti-
human C5b9 (Calbiochem, San Diego, CA, USA) and Alex-
a488-labelled anti-rabbit (Life Technologies, Carlsbad, CA,
USA) were used. The results were compared with pooled
normal human serum (NHS) run in parallel.
Statistical analysis
Continuous variables were presented as mean (SD) or
median [interquartile range (IQR)] as appropriate. Descrip-
tive statistics were used to analyze the cohort. Ex vivo C5b9
formation on HMEC-1 was compared with NHS by the




Twenty-five women with primary aHUS and five asymp-
tomatic relatives were recruited from the Limburg Renal Reg-
istry (n = 18) and Cliniques Universitaires Saint-Luc
(n = 12). Eleven nulliparous women (three asymptomatic
relatives) were excluded; one of them with three episodes of
primary aHUS with a background of a pathogenic variant in
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C3 remained intentionally childless to lower the risk of
relapse.
Thus, 19 women at risk for complement dysregulation
and a total of 39 pregnancies were analyzed (Table 1). Rare
variants in complement genes were found in eight (47%) out
of 17 patients with primary aHUS; combined variants were
identified in one case. Five variants in six carriers were con-
sidered pathogenic (Table 2). A pathogenic variant in CD46
was identified in two asymptomatic relatives (patient no.
M12, B7). The at-risk haplotypes CFH-H3 and MCPGGAAC
were found in three and two patients with primary aHUS,
respectively, but not in asymptomatic carriers. The homozy-
gous genomic deletion of CFHR1 and CFHR3 but no factor
H autoantibodies were identified in one patient with primary
aHUS. Massive ex vivo C5b9 formation on HMEC-1 con-
firmed unrestrained complement activation in nine patients
with no variants identified at the time of acute primary
aHUS. The patients’ disease courses can be found in
Table SI.
Maternal complications of pregnancy
We analyzed 39 pregnancies, all of whom were managed with
no prophylactic measures.
P-aHUS developed in seven (18%) out of 39 pregnancies
at the time of delivery (n = 4) or postpartum (n = 3); four
episodes were linked to the first pregnancy. Patients invari-
ably presented with severe kidney failure (median serum cre-
atinine 492 µmol/l; IQR, 194–557), including six patients
who needed dialysis. Low platelets and Coombs negative
microangiopathic haemolytic anaemia were observed in five
patients. Major bleeding, requiring blood and platelet trans-
fusion, precipitated P-aHUS in one patient. Pre-eclampsia
and HELLP were clinically inferred prior to the recognition
of P-aHUS in four and one patient respectively. Plasma
exchange with fresh frozen plasma was started in six patients
and associated with a complete clinical response in two
cases, that is, normalization of kidney function. Eculizumab,
a potent C5 inhibitor, was started in three refractory
patients; two patients who initially required dialysis recov-
ered kidney function and improved to CKD stage G2, while
the other patient progressed to ESKD. The patient not
treated with plasma exchange was diagnosed with pre-
eclampsia, but proved to have acute TMA on kidney biopsy,
and progressed to CKD G4; ESKD developed after a subse-
quent pregnancy complicated by pre-eclampsia and major
bleeding.
Five (16%) out of 32 pregnancies not linked to P-aHUS
were complicated by pre-eclampsia (n = 4, 125%) and
HELLP (n = 1, 3%). Furthermore, one patient had gesta-
tional hypertension. No maternal complications occurred in
26 (67%) out of 39 pregnancies, including 10 (71%) out of
14 pregnancies from carriers of rare variants in complement
genes (five patients with primary aHUS and two relatives
with 11 and three pregnancies respectively).
Fetal outcomes
Fetal outcomes of all 39 pregnancies are depicted in Table 3.
Thirty-five (90%) out of the 39 pregnancies resulted in live
birth, three pregnancies resulted in a spontaneous abortion,
and one pregnancy was terminated at week 14 for unknown
reasons. Twenty-two (63%) out of the 35 live births occurred
at full term, 10 (29%) at preterm and two (6%) at postterm.
Eight of the preterm deliveries were induced because of pre-
eclampsia, HELLP and/or P-aHUS, the extremely preterm
infant (i.e. gestational week 26 + 2) died from infantile respi-
ratory distress syndrome two days after delivery. Pregnancies
complicated by P-aHUS resulted in eight newborns. Three
(38%) were small for gestational age and one died from
asphyxiation.
Long-term kidney outcome after pregnancy
The women were followed for a median of 13 (IQR, 3–36)
and 31 (IQR, 15–79) years after their first pregnancy and
the onset of primary aHUS respectively. At last follow-up, six
patients and one asymptomatic relative had normal kidney
function, that is, an estimated glomerular filtration rate
>60 ml/min/173 m2. Two patients had progressed to CKD
G3, one to CKD G4 and eight patients to ESKD; one asymp-
tomatic relative had progressed to CKD G3 but primary
aHUS never developed.25 The rate of ESKD in all 19 women
after the first pregnancy was 295 (95% CI, 137–561) per
100 person-years; after excluding both asymptomatic rela-
tives, the rate of ESKD was 372 (95% CI, 275–716) per 100
person-years. In total, seven donor kidneys were transplanted
in five recipients, all of whom had a high estimated risk for
primary aHUS to reoccur.13 None of the recipients became
pregnant.
Discussion
Pregnancy is a critical condition in women predisposed to
complement dysregulation as it can precipitate primary
aHUS with the attendant risk of sequalae. The first episode
of primary aHUS can be linked to pregnancy, that is, P-
aHUS, in up to 20% of women.9 P-aHUS can occur as often
in the first pregnancy as in subsequent pregnancies. Numer-
ous women at risk therefore decided not to become preg-
nant. Here, we demonstrate that the risk of pregnancy in
women predisposed to complement dysregulation may be
too pessimistic. P-aHUS occurred in <20% of pregnancies in
the setting of additional potential precipitants, while the bur-
den of pre-eclampsia and HELLP appeared lower than appre-
ciated. Rare variants in complement genes did not predict
the course of a given pregnancy.
The clinical course of P-aHUS resembles primary aHUS
and has been linked to the first pregnancy in ~50% patients,9
suggesting a high burden of complicated pregnancies in
women with primary aHUS. Previous studies, however, did
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not report on uncomplicated pregnancies in detail. In our
study, the incidence of P-aHUS as well as pre-eclampsia and
HELLP appeared lower than anticipated. Gaggl et al.11 cor-
roborated our findings, indicating that uncomplicated preg-
nancies are common among women predisposed to
complement dysregulation, including those with pathogenic
variants in complement genes. Most of these variants have
been linked to complement dysregulation on the endothe-
lium and require a precipitating factor26 before primary
aHUS can manifest. We confirm that rare variants per se can-
not predict the risk of P-aHUS in a given pregnancy, under-
scoring the key role of additional precipitants, such as
bleeding and hypertension.11
Rare variants in complement genes were found in half the
patients with primary aHUS, identical to findings in two
large registries.2,3 DNA testing of genes encoding comple-
ment proteins showed that variants can also be found in
women with pre-eclampsia4 and HELLP,5,6 although conflict-
ing results have been reported.27,28 Most of these studies,
however, report on variants in complement genes of either
uncertain or no significance, overestimating the prevalence of
disease-causing variants.19 Moreover, pre-eclampsia or
HELLP may develop in pregnant women on eculizumab
treatment.29,30 Placental release of antiangiogenic factors,
such as soluble Fms-like tyrosine kinase 1, appeared more
relevant for both conditions to develop.31
It should be emphasized that women with pre-eclampsia
or HELLP may in fact have P-aHUS. This is particularly the
case in patients with severe kidney disease not improving
after delivery. In one-third of patients with P-aHUS, ESKD
can develop within three months after presentation,9
contrasting the low risk of ESKD linked to pre-eclampsia.32
Kidney tissue specimens can aid the differential diagnosis as
acute TMA and in particular glomerular thrombosis, and
favour a diagnosis of P-aHUS.33 The correct recogni-
tion of patients with P-aHUS is of utmost importance
given the potential benefit of therapeutic complement
inhibition.34–36
The outcome of pregnancies appeared favourable,
although the long-term kidney outcome resembled primary
aHUS with high rates of ESKD.2,3 Management of pregnant
women with primary aHUS or asymptomatic relatives has
not been delineated in current guidelines.1 Prophylactic
plasma infusions during pregnancy have been proposed,11
identical to treatment for thrombotic thrombocytopenic pur-
pura.37 Prophylactic treatment, however, is debatable as preg-
nancy is a predictable event, the penetrance of primary
aHUS in normal pregnancy is low, and the typical occur-
rence is in the postpartum period. Eculizumab, however, has
been proven safe, both for mother and child,30 and effec-
tive9,38 for the treatment of P-aHUS. Pregnancy is therefore
not contraindicated in women predisposed to complement
dysregulation, although close and careful monitoring in cen-
tres of expertise is warranted for at least three months after
delivery. In patients with active disease, eculizumab should
be immediately available. These data, however, cannot be
extrapolated to patients diagnosed with primary aHUS and
sequalae, such as hypertension and CKD. Future prospective
studies are therefore needed to optimize the management of
women predisposed to complement dysregulation.
Placentation and immunologic adaptation of the mother
are key processes for pregnancy to succeed. In vivo studies
linked complement dysregulation to growth restriction and
fetal loss.8,39 Most of the newborns, however, were appropri-
ate for gestational age. Of note, placental complement regula-
tion depends on membrane-bound CD55 and CD59.40 Both
proteins have not been implicated in the mechanism of pri-
mary aHUS, suggesting a normal feto–maternal crosstalk.
In conclusion, our data emphasized the high frequency of
successful pregnancies in women predisposed to complement
dysregulation. Rare variants in complement genes cannot be
used to predict the risk of a given pregnancy as additional
potential precipitants are often needed for P-aHUS to mani-
fest.
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Table III. Fetal outcome of the 39 pregnancies.
No. P P-aHUS Year Outcome Sex Delivery Weight, g Gestational week
M1 1  2000 Live birth F Vaginal 2480† 38
2  2001 Live birth/died from IRDS (+3 days) M Vaginal 890 26 + 2
3 + 2002 Live birth M Vaginal 2975 37
M2 1  1982 Live birth F Vaginal 2450† 40
M3 1  2004 Live birth M/M Vaginal* 2655/2580 36 + 5
M4 1  2009 Live birth M Vaginal 3640 40
M5 1  2002 Live birth M Vaginal* 3435 39
2  2005 Live birth M Vaginal 3600 Full term
3  ND Provoked abortion (14th wk)
4  2007 Live birth M Vaginal 3290 Full term
5  ND Spontaneous abortion (unknown)
6 + 2013 Live birth, IUGR M/M Vaginal* 1120†/1300† 33 + 0
7  2014 Live birth, IUGR F CS* 1001† 31 + 2
M6 1  2011 Live birth M CS* 1460† 31 + 5
M7 1  1973 Live birth M Vaginal Normal Full term
2  1974 Live birth M Vaginal Normal Full term
3  ND Spontaneous abortion (6th wk)
4  1978 Live birth M Vaginal Normal Full term
M8 1  1997 Live birth M Vaginal Normal 39
2  1999 Live birth M Vaginal Normal 38
3  2004 Spontaneous abortion (13th wk)
4  2005 Live birth M Vaginal Normal 42
M9 1 + 2016 Live birth F Vaginal 3255 39 + 5
M10 1  1969 Live birth M Vaginal Normal Full term
2  1970 Live birth M Vaginal Normal Full term
3  1975 Live birth F Vaginal Normal Full term
M11 1 + 2019 Live birth/died from asphyxia (+4 days) M CS Normal Full term
M12 1  1966 Live birth M ND ND ND
B1 1  2005 Live birth M CS* 1500† 32 + 0
2 + 2016 Live birth F CS* 1250† 31 + 3
B2 1 + 2017 Live birth F CS* 2350 35 + 6
B3 1  2016 Live birth M Vaginal 2675 35 + 5
B4 1  1971 Live birth M Vaginal 3500 Full term
2  1978 Live birth F Vaginal 3200 Full term
B5 1  2014 Live birth M Vaginal 3885 42 + 0
2  2017 Live birth F Vaginal 3370 38 + 0
B6 1 + 2018 Live birth F CS* 1380 31 + 0
B7 1  2012 Live birth F Vaginal 2850 39 + 2
2  2013 Live birth F Vaginal 3060 40 + 2
B1–7, Brussels cohort; CS, Caesarean section; F, female; IRDS, infantile respiratory distress syndrome; IUGR, intrauterine growth restriction; M,
male; M1–12, Maastricht cohort; ND, not documented; P, pregnancy.
*Induced labour or CS.
†Small for gestational age, defined as a birth weight below the 10th percentile for gestational age.
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